Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 3
2008 3
2009 15
2010 16
2011 22
2012 30
2013 24
2014 36
2015 36
2016 33
2017 26
2018 38
2019 36
2020 35
2021 70
2022 48
2023 48
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

444 results

Results by year

Filters applied: . Clear all
The following term was ignored: )
Page 1
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, Vredenburg M, Cuker A. Al-Samkari H, et al. Br J Haematol. 2022 May;197(3):359-366. doi: 10.1111/bjh.18081. Epub 2022 Feb 18. Br J Haematol. 2022. PMID: 35179784 Free PMC article.
Limited data are available describing outcomes in patients who switched from romiplostim or eltrombopag to avatrombopag, a newer oral TPO-RA. We performed a retrospective observational study of adults with ITP who switched from eltrombopag or romipl …
Limited data are available describing outcomes in patients who switched from romiplostim or eltrombopag to avatrombopag …
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
Jurczak W, Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, Allen LF. Jurczak W, et al. Br J Haematol. 2018 Nov;183(3):479-490. doi: 10.1111/bjh.15573. Epub 2018 Sep 7. Br J Haematol. 2018. PMID: 30191972 Free PMC article. Clinical Trial.
Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6-month, multicentre, randomised, double-blind, parallel-group Phase 3 study, with an open-label extension phase, to assess the efficacy and safety of avatrombopag (20 mg/day) in a …
Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6-month, multicentre, randomised, double-blind, …
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Cheng G, et al. Lancet. 2011 Jan 29;377(9763):393-402. doi: 10.1016/S0140-6736(10)60959-2. Epub 2010 Aug 23. Lancet. 2011. PMID: 20739054 Clinical Trial.
We aimed to compare the response to once daily eltrombopag versus placebo in patients with chronic immune thrombocytopenia during a 6-month period. ...Four (7%) patients taking placebo had serious bleeding events, compared with one (<1%) patient treated with e …
We aimed to compare the response to once daily eltrombopag versus placebo in patients with chronic immune thrombocytopenia dur …
Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB. Wong RSM, et al. Blood. 2017 Dec 7;130(23):2527-2536. doi: 10.1182/blood-2017-04-748707. Epub 2017 Oct 17. Blood. 2017. PMID: 29042367 Free article. Clinical Trial.
In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced bleeding. The open-label EXTEND study evaluated long-term safety and efficacy of eltrombopag …
In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with chronic/persistent immune thrombocytopenia (IT …
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, Cheng P, Huang R, Yang L, Hu J, Hou M, Yao Y, Liu L, Wang Y, Wu D, Zhang L, Zheng C, Shen X, Hu Q, Liu J, Jin J, Luo J, Zeng Y, Gao S, Zhang X, Zhou X, Shi Q, Xia R, Xie X, Jiang Z, Gao L, Bai Y, Li Y, Xiong J, Li R, Zou J, Niu T, Yang R, Hu Y. Mei H, et al. J Hematol Oncol. 2021 Feb 25;14(1):37. doi: 10.1186/s13045-021-01047-9. J Hematol Oncol. 2021. PMID: 33632264 Free PMC article. Clinical Trial.
Patients who received placebo and completed 10 weeks of treatment switched to receive eltrombopag, and patients treated with hetrombopag in the double-blind period continued hetrombopag during the following open-label 14-week treatment. ...The most common adverse events we …
Patients who received placebo and completed 10 weeks of treatment switched to receive eltrombopag, and patients treated with hetrombo …
Eltrombopag.
Garnock-Jones KP, Keam SJ. Garnock-Jones KP, et al. Drugs. 2009;69(5):567-76. doi: 10.2165/00003495-200969050-00005. Drugs. 2009. PMID: 19368418
The drug acts via the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway to activate megakaryocyte proliferation and differentiation in bone marrow progenitor cells, similar to those observed with endogenous thrombopoietin. Platelet counts are increa …
The drug acts via the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway to activate megakaryocyte proliferati …
Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy.
Palumbo G, Farruggia P, Ramenghi U, Russo G, Borchiellini A, Spinelli M, Dufour C, Giona F, Ladogana S, Zecca M, Perrotta S, Pession A, Giordano P. Palumbo G, et al. Hematology. 2023 Dec;28(1):2210906. doi: 10.1080/16078454.2023.2210906. Hematology. 2023. PMID: 37199369
BACKGROUND: Immune thrombocytopenia (ITP) is the most common acquired bleeding disorder. ...When second-line therapy is needed in the pediatric setting, current guidelines recommend eltrombopag as the drug of choice. PROCEDURE: The aim of this article is to summariz …
BACKGROUND: Immune thrombocytopenia (ITP) is the most common acquired bleeding disorder. ...When second-line therapy is needed in the …
An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
Song AB, Al-Samkari H. Song AB, et al. Expert Rev Clin Immunol. 2022 Aug;18(8):783-791. doi: 10.1080/1744666X.2022.2098119. Epub 2022 Jul 10. Expert Rev Clin Immunol. 2022. PMID: 35793401
AREAS COVERED: We provide an overview of the thrombopoietin receptor agonists with a particular focus on avatrombopag, the newest agent in this class. In phase II and III clinical trials, avatrombopag was shown to offer durable improvement in platelet counts. ...It …
AREAS COVERED: We provide an overview of the thrombopoietin receptor agonists with a particular focus on avatrombopag, the newest age …
Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis.
Li T, Liu Q, Pu T, Liu J, Zhang A. Li T, et al. Expert Opin Pharmacother. 2023 Apr;24(6):763-774. doi: 10.1080/14656566.2023.2198089. Epub 2023 Apr 6. Expert Opin Pharmacother. 2023. PMID: 37010022
INTRODUCTION: In this paper, we systematically review the efficacy and safety of thrombopoietin receptor agonists (TPORAs) for treatment of persistent and chronic immune thrombocytopenia (ITP) in children and adults. METHODS: We searched PubMed, MEDLINE, ScienceDirect, Sco …
INTRODUCTION: In this paper, we systematically review the efficacy and safety of thrombopoietin receptor agonists (TPORAs) for treatment of …
Avatrombopag for adults with early versus chronic immune thrombocytopenia.
Virk ZM, Leaf RK, Kuter DJ, Goodarzi K, Connell NT, Connors JM, Al-Samkari H. Virk ZM, et al. Am J Hematol. 2024 Feb;99(2):155-162. doi: 10.1002/ajh.27080. Epub 2023 Dec 8. Am J Hematol. 2024. PMID: 38063420
We hypothesize that avatrombopag has similar safety and effectiveness irrespective of ITP disease phase. ...Seventy-five patients were included, 23 with newly diagnosed/persistent ITP (17.7 patient-years of avatrombopag treatment) and 52 with chronic ITP (65.3 patie …
We hypothesize that avatrombopag has similar safety and effectiveness irrespective of ITP disease phase. ...Seventy-five patients wer …
444 results